GO
Loading...

Regeneron Pharmaceuticals Inc

More

  • US STOCKS-Wall St edges up, S&P rises back above 2,000 Tuesday, 26 Aug 2014 | 10:35 AM ET

    *Best Buy tumbles after results, DSW higher. *Digital Ally gains again, has tripled this month. "People aren't going to do anything too aggressive until there's some kind of catalyst, either positive or negative, and we may end up consolidating around 2,000 for a while," said Michael O'Rourke, chief market strategist at JonesTrading in Greenwich, Connecticut.

  • Biotechs rallied after Roche Holding AG agreed to buy InterMune Inc for $8.3 billion in cash, the latest vote of confidence in a sector that many, including Federal Reserve Chair Janet Yellen, are worried is overvalued. InterMune jumped 36 percent to $73.00, with the Nasdaq Biotech index up 2.4 percent.

  • Aug 5- Regeneron Pharmaceuticals Inc on Tuesday reported higher-than-expected quarterly revenue and earnings on surging demand for its Eylea treatment for macular degeneration, and stuck to its full-year sales forecast for the drug.

  • *Twitter rallies after blockbuster results. NEW YORK, July 30- U.S. stocks were flat on Wednesday, paring earlier gains as a strong read on second-quarter economic growth sparked concerns the Federal Reserve may adjust its stimulus earlier than expected.

  • *Twitter rallies after blockbuster results. *Biotechs rally on Amgen results, Regeneron trial data. Twitter Inc surged on heavy volume, jumping 25 percent to $48.25 in its biggest one-day advance ever after reporting that monthly active users had risen a better-than-expected 24 percent in the second quarter.

  • Cramer: These 2 biotech stocks are going higher Wednesday, 30 Jul 2014 | 9:48 AM ET
    Jim Cramer

    CNBC's Jim Cramer on Wednesday identified two biotechnology stocks that he thinks could climb.

  • FDA OKs expanded use of Regeneron's eye drug Tuesday, 29 Jul 2014 | 10:29 PM ET

    Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.

  • Aced the SAT? Try this Cramer question Wednesday, 23 Jul 2014 | 6:19 PM ET

    If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.

  • Early movers: UNH, BAC, IBM, COST, LL, WDFC & more Thursday, 10 Jul 2014 | 7:48 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Cramer: 4 strong stocks for months to come Wednesday, 9 Jul 2014 | 6:29 PM ET

    If the charts are to be believed, the path of least resistance for these 4 stocks should be higher.

  • Midday movers: Lorillard, PetSmart, Walgreen & More Thursday, 3 Jul 2014 | 11:58 AM ET

    Some of Thursday's midday movers:

  • Cramer: Six buyable themes in second half Tuesday, 1 Jul 2014 | 6:08 PM ET
    Jim Cramer on Mad Money.

    Cramer says the price action in Tuesday’s market is sending an important message about what to buy in the days ahead.

  • Midday movers: Alstom, CarMax, Sprint & More Friday, 20 Jun 2014 | 11:34 AM ET

    Some of Friday's midday movers:

  • Beleaguered biotechs about to rally: Charts Wednesday, 4 Jun 2014 | 6:26 PM ET

    For the past several months biotech stocks have fallen out of favor on Wall Street. That may be about to change.

  • Valeant's New York- listed shares dropped 1 percent by midday to $128.66, paring earlier losses, while Allergan stock lost 4.1 percent to $158.29. Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30.

  • Valeant increases bid for Botox-maker Allergan Wednesday, 28 May 2014 | 12:09 PM ET
    Botox by Allergan

    Canadian drugmaker Valeant Pharmaceuticals International raised the cash component of its offer for Botox-maker Allergan by $10 per share.

  • UPDATE 2-Valeant injects cash into bid for Botox maker Wednesday, 28 May 2014 | 9:06 AM ET

    Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30. The new offer values Allergan at $166.16 per share as of Tuesday's closing price, and is about 8.6 percent higher than the previous bid of $153 as on April 22 when Valeant first made its offer.

  • Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30. The new offer values Allergan at $166.16 per share as of Tuesday's closing price, and is about 8.6 percent higher than the previous bid of $153 as on April 22 when Valeant first made its offer.

  • TIMELINE-Early signs of pushback over U.S. drug prices Wednesday, 28 May 2014 | 1:00 AM ET

    May 28- Gilead Sciences' $84,000 treatment for hepatitis C, Sovaldi, has broken the sales record for drug launches and caused a backlash among insurers concerned by the cost.

  • Top 10 highest paid CEOs Tuesday, 27 May 2014 | 7:42 AM ET
    Les Moonves, president and chief executive officer of CBS Corp.

    Here are the 10 highest-paid CEOs of 2013, as calculated by The Associated Press and Equilar, an executive pay research firm.